Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30648987 | 0.96 | ALDH1A1 (0.42) | KDM4EPOLBALDH1A1TSHREGLN1 | |
| SCHEMBL2607368 | 0.85 | KDM4E (0.40) | KDM4EALDH1A1EGLN1SMN1; SMN2CYP2D6 | |
| SCHEMBL21806079 | 0.84 | KDM4E (0.50) | KDM4EPOLBALDH1A1TSHRTHRB | |
| SCHEMBL22444994 | 0.82 | ALDH1A1 (0.41) | KDM4EALDH1A1TSHRTHRBSMN1; SMN2 | |
| SCHEMBL7220626 | 0.80 | EPHX2 (0.39) | TSHREGLN1THRBEPHX2LTA4H | |
| SCHEMBL7720634 | 0.80 | LTA4H (0.36) | TSHREGLN1SMN1; SMN2LTA4H | |
| SCHEMBL25148186 | 0.79 | ALDH1A1 (0.47) | KDM4EPOLBALDH1A1TSHRTHRB | |
| SCHEMBL20535410 | 0.79 | ALDH1A1 (0.41) | KDM4EALDH1A1TSHREGLN1SMN1; SMN2 | |
| SCHEMBL13793645 | 0.79 | KDM4E (0.42) | KDM4EPOLBALDH1A1TSHRTHRB | |
| SCHEMBL30547298 | 0.79 | EGLN1 (0.37) | KDM4EPOLBALDH1A1EGLN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-11807664-B2 | Method for producing cyclic organic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-07 | — | — | US | disclosed |
| US-11807664-B2 | Method for producing cyclic organic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-07 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20210147475-A1 | METHOD FOR PRODUCING CYCLIC ORGANIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-05-20 | — | — | US | disclosed |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3636807-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-04-15 | — | — | EP | disclosed |
| CN-110869544-A | Cyclic peptide compound having high membrane permeability and library containing same | 中外制药株式会社 | 2020-03-06 | — | — | CN | disclosed |
| US-20200040372-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| US-8273776-B2 | Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators | ALLERGAN, INC (US) | 2012-09-25 | — | — | US | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-20110257232-A1 | BIPHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040372-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | AARS1, NSUN3, RNGTT | KDM4E 3061/4885POLB 902/4885ALDH1A1 4757/4885 |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | VIP, SLC7A1, TRPV1 | KDM4E 4113/4885POLB 4724/4885ALDH1A1 4817/4885 |
| US-20210147475-A1 | METHOD FOR PRODUCING CYCLIC ORGANIC COMPOUND | SCTR, CTRC, DCXR | KDM4E 4119/4885POLB 994/4885ALDH1A1 4749/4885 |
| US-20110257232-A1 | BIPHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTORS MODULATORS | S1PR3, S1PR1, S1PR2 | KDM4E 3392/4885POLB 4160/4885ALDH1A1 2444/4885 |
| US-11807664-B2 | Method for producing cyclic organic compound | SCTR, CTRC, DCXR | KDM4E 4119/4885POLB 994/4885ALDH1A1 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.